{"id":"NCT00992459","sponsor":"Amgen","briefTitle":"Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders","officialTitle":"A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2009-10-09","resultsPosted":"2013-08-12","lastUpdate":"2024-07-09"},"enrollment":46,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Urea Cycle Disorders"],"interventions":[{"type":"DRUG","name":"HPN-100","otherNames":["GT4P, glyceryl tri-(4-phenylbutyrate)"]},{"type":"DRUG","name":"Buphenyl (NaPBA)","otherNames":["sodium phenylbutyrate"]}],"arms":[{"label":"Buphenyl (NaPBA) /HPN 100 Placebo","type":"EXPERIMENTAL"},{"label":"HPN-100/NaPBA Placebo","type":"EXPERIMENTAL"}],"summary":"This was a randomized, active-controlled, double-blind, cross-over study designed to enroll subjects with UCDs who are being treated with NaPBA.","primaryOutcome":{"measure":"The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28.","timeFrame":"pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28","effectByArm":[{"arm":"NaPBA","deltaMin":976.6,"sd":865.9},{"arm":"HPN-100","deltaMin":865.35,"sd":660.53}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":22,"countries":["United States","Canada"]},"refs":{"pmids":["22961727","24144944"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":45},"commonTop":["diarrhea","headache","flatulence","abdominal pain","decreased appetite"]}}